Internal Medicine, Rheumatology · Houston, TX
NPI
1588630578
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
11003 Resource Pkwy Ste 104
Houston, TX, 77089
Phone (281) 481-8557
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
93,485 services
Medicare patients, 2024
349
Average age 73
Drug cost, 2024
$5.6M
4,825 prescriptions
Company payments, 2025
$1,246
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Philip A Waller was code J1602 (injection, golimumab, 1 mg, for intravenous use), 15,500 times for 16 patients. In total Philip A Waller billed 93,485 services in 49 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-05-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 15,500 | 16 | $9.04 | $140K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 8,975 | 15 | $33.81 | $303K |
| J0897 Injection, denosumab, 1 mg | Office | 6,720 | 65 | $20.37 | $137K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 5,030 | 46 | $0.10 | $491 |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 4,940 | 16 | $24.71 | $122K |
| 99214 Office E&M - Established | Office | 455 | 221 | $81.47 | $37K |
| 99213 Office E&M - Established | Office | 412 | 226 | $59.22 | $24K |
| 96413 Chemotherapy Administration | Office | 398 | 64 | $94.19 | $37K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 324 | 187 | $11.46 | $3,713 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 294 | 13 | $0.23 | $67.08 |
| 96401 Chemotherapy Administration | Office | 189 | 76 | $52.58 | $9,937 |
| 96415 Chemotherapy Administration | Office | 105 | 20 | $20.45 | $2,148 |
| 96372 Injection Administration | Office | 78 | 41 | $9.67 | $754 |
| 77080 Standard X-ray | Office | 63 | 63 | $35.95 | $2,265 |
| 20610 Joint Injection | Office | 42 | 22 | $44.67 | $1,876 |
By year: 2022 $1.2M for 72,517 services; 2023 $1.2M for 80,528 services; 2024 $1.2M for 93,485 services.
Medicare prescription drug claims, 2024
In 2024, the drug Philip A Waller prescribed most often to Medicare patients was Prednisone, with 536 prescriptions and refills. In total Philip A Waller wrote 4,825 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 536 | 1,135 | 228 | $3,771 |
| Hydroxychloroquine Sulfate Generic | 532 | 1,319 | 203 | $24K |
| Methotrexate Methotrexate Sodium | 431 | 1,039 | 172 | $12K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 334 | 334 | 46 | $11K |
| Prolia Denosumab | 241 | 1,446 | 147 | $407K |
| Gabapentin Generic | 207 | 418 | 78 | $2,906 |
| Tramadol Hcl Generic | 150 | 172 | 52 | $987 |
| Leflunomide Generic | 142 | 372 | 56 | $13K |
| Methylprednisolone Generic | 111 | 192 | 69 | $2,707 |
| Celecoxib Generic | 101 | 251 | 44 | $4,885 |
| Folic Acid Generic | 99 | 266 | 43 | $648 |
| Alendronate Sodium Generic | 89 | 240 | 38 | $817 |
| Duloxetine Hcl Generic | 76 | 182 | 24 | $1,897 |
| Zoledronic Acid Zoledronic Acid/Mannitol-Water | 75 | 633 | 75 | $9,722 |
| Humira(Cf) Pen Adalimumab | 72 | 92 | 15 | $900K |
Brand drugs: 1,028 claims; generic drugs: 3,777 claims; opioid claims: 554.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Philip A Waller $1,246 ($1,246 in general payments such as food, travel and fees) from 25 companies. The largest payer was Abbvie Inc. with $272.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 20 | $272 |
| Janssen Biotech, Inc. JNJ | 7 | $263 |
| Pfizer Inc. PFE | 6 | $149 |
| UCB, Inc. UCB.BR | 6 | $126 |
| GlaxoSmithKline, LLC. GSK | 5 | $92.55 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $72.53 |
| Biogen, Inc. BIIB | 2 | $49.98 |
| ANI Pharmaceuticals, Inc. ANIP | 2 | $45.35 |
| Fresenius Kabi USA, LLC | 2 | $42.9 |
| Sobi, Inc SOBI.ST | 1 | $26.08 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.